Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA
FARA Research Priorities & Grant Program

FARA supports research across the spectrum from basic research through drug development and clinical research programs in FA. All investigators interested in FA-related research are invited to submit a Letter of Intent (LOI) through our submission portal. For more information on how to apply for a FARA grant, click here. FARA particularly encourages junior investigators to submit LOIs. FARA also accepts LOIs from biopharmaceutical companies and other industry entities. All proposed research must fall within FARA's Grant Program Priorities, which are as follows:
 
 

FARA Grant Program Priorities
Advancing understanding of neuroscience/ systems Understanding the neurodegeneration of FA and implications for therapies.
Advancing understanding of cardiac disease in FA Understanding the cardiomyopathy associated with FA and developing therapies to reduce the morbidity and mortality caused by cardiac disease in FA.
Advance drug discovery Highest priority in this category will be given to genetic, epigenetic, and protein approaches that target increasing frataxin levels. We also strongly consider high probability projects relating to therapeutics in pathways likely to affect the disease progression or disease symptoms.
Facilitate the drug development process and translational research FARA aims to support promising discoveries and to facilitate the rapid translation of those works into the clinic.

Highest priority in this category will be given to IND-enabling studies, as well as discovery and validation of clinical outcome measures and/or biomarkers.
Advance clinical research FARA supports efforts to enable effective clinical research. These include: natural history studies, discovery and validation of clinical outcome measures and/or biomarkers, identification of early (including pre-symptomatic) quantifiable clinical features, patient reported outcomes, investigator-initiated clinical trials, and evidence-based clinical treatment guidelines.

Highest priority in this category will be given to clinical research that utilizes or expands resources of the Collaborative Clinical Research Network in FA. As well, highest priority in this category will be given to continued development of biomarker discovery and validation, and early phase or pilot clinical studies.

 
 
 
 
Grant types, Deadlines, and Budget Limits
Grant Type Letter of Intent
(LOI) Deadline
Application Deadline Maximum Budget
(in US dollars)
 +  General Research Grant February 1 & July 15 April 1 & September 15 $150,000 per year
for 1 or 2 years
 +  Keith Michael Andrus
Cardiac Award
January 15 March 1 $150,000 per year
for 1 or 2 years
 +  Kyle Bryant Translational
Research Award
May 15 July 15 $250,000 per year
for 1 or 2 years
 +  Bronya J. Keats
International Research
Collaboration Award
May 15 July 15 $200,000 per year
for 1 or 2 years
 +  Postdoctoral
Research Award
February 1 & July 15 April 1 & September 15 $100,000 per year
for 1 or 2 years
 +  Postdoctoral
Fellowship
February 1 & July 15 April 1 & September 15 Trainee salary
up to 2 yrs
 +  Request for Proposals
and Ad-hoc Requests
FARA will issue requests for proposals (RFPs) on an ad-hoc basis.
 
 
 

For junior investigators and postdoctoral and graduate trainees who would like support through the application process or general advice on grant writing, they may contact FARA at  grants@curefa.org  for assistance.

 
 
 
 Tips & Site Navigation 

 
 

Research Announcements

  • Are you subscribed to our science newsletter, Friedreich's ataxia Community Research News?
    If you are not a subscriber, please click here to sign-up!
Stayed tuned for more research announcements! 
 

SHARE

FacebookTwitterLinkedInYoutube
Event E.jpg